| Literature DB >> 34775947 |
Daniel Joseph Warrington1, Elizabeth Jane Shortis2, Paula Jane Whittaker2.
Abstract
BACKGROUND: Falls are a common and serious health issue facing the global population, causing an estimated 646,000 deaths per year globally. Wearable devices typically combine accelerometers, gyroscopes and even barometers; using the data collected and inputting this into an algorithm that decides whether a fall has occurred. The purpose of this umbrella review was to provide a comprehensive overview of the systematic reviews on the effectiveness of wearable electronic devices for falls detection in adults.Entities:
Keywords: Accidental falls; Aged; Falls management; Falls prevention; Wearable electronic devices
Mesh:
Year: 2021 PMID: 34775947 PMCID: PMC8591794 DOI: 10.1186/s12889-021-12169-7
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Methodology of included systematic reviews and meta-analyses
| Author | Number of and year of publication of included studies | Databases Searched | Study Objective | Population | Sample Size | Type of Device | Main Results |
|---|---|---|---|---|---|---|---|
CINAHL Embase MEDLINE Compendex | To summarise and critically examine evidence regarding the detection of near falls (slips, trips, stumbles, missteps, incorrect weight transfer, or temporary loss of balance) using wearable devices. | Adults (aged > = 18 years of age) | Average per study = 21 participants Total = 192 participants | ||||
Springerlink Elsevier IEE Xplore Digital Library Multidisciplinary Digital Publishing Institute (MDPI) | To systematically evaluate the use of Internet of Things (IoT) technology, especially in terms of sensing techniques and data processing techniques in performing falls management for supporting older adults to live independently and safely. | Adults (aged > = 18 years of age) | Average per study = 7 participants Total = 170 participants | Wearable devices are effective for falls detection - achieving high specificity, sensitivity, and accuracy. Heterogenous methodology in the included studies make quantitative interpretation difficult. | |||
PubMed Embase IEEE Xplore Cochrane Central Registry of Controlled Trials (CENTRAL) World Health Organisation International Clinical Trials Registry Platform | To synthetize the empirical evidence regarding inertial sensor-based falls risk assessment and prediction to identify optimal combination of sensor placement, task and features aiming to support evidence-based design of new studies and real-life applications. | At least 10 participants with an average age of 60 years old or over with no severe cognitive or motor impairment. Studies in which participants were labelled as fallers and non-fallers. | Average per study = 93 Total = 1211 participants | The statistical analysis of features reported in the 13 shortlisted studies revealed significant, very strong, positive associations in 3 different triads of feature category, task, and sensor placement: • Angular velocity – Walking – Shins • Linear acceleration – Quiet standing – Lower back • Linear acceleration – Stand to sit/Sit to stand – Lower back | |||
PubMed CINAHL Embase PsycINFO | To systematically assess the current state of design and implementation of fall detection devices. This review also examines the extent to which these devices have been tested in the real world as well as the acceptability of these devices to older adults. | Adults (aged > = 18 years of age) | Information not available | Most common types of devices: • Systems with device on trunk. Median sensitivity = 97.5% (range 81–100). Median specificity = 96.9% (range 77–100) • Systems involving multiple sensors. Median sensitivity = 93.4% (range 92.5–94.2) and a median specificity of 99.8% (range 99.3–100). • Systems involving devices around arms, hands, ears, or feet had a lower median sensitivity and specificity [81.5% (range 70.4–100) and 83% (range 80–95.7) respectively]. | |||
| N = 4 (2005–2015) | PubMed Web of Science databases | To provide an overview of the use of wearable systems to assess freezing of gait (FOG) and falls in Parkinson’s disease with emphasis on device setup and results from validation procedures. | Parkinson disease patients (aged > = 18 years of age) | Average per study = 44 participants Total = 177 participants | High specificity (86.4–98.6%) and sensitivity (93.1% only one study) for wearable device detection of falls. | ||
IEEE Xplore SpringerLink Science Direct PubMed | To provide an overview of the most adopted sensing technologies in these fields, with a focus on the type of sensors (rather than algorithms), their position on the body and the kind of tasks they are used in. | Healthy “aged” population | Average per study = 32 participants Total = 1331 participants | • Single sensor = 70% use accelerometer • Two sensors = 1) Approaches that combine accelerometer with a pressure sensor (usually in shoes). 2) Approaches that use accelerometer and gyroscope sensors (usually on same electronic board). • Three or more sensors = other sensing technology used (magnetometer, camera, EMG). • Sensor placement = mainly on the trunk. Second most likely position is foot or leg (about 30%). | |||
PubMed Web of Science Cochrane Library CINAHL | To systematically evaluate the use of technology in performing fall risk assessments, and more specifically, to evaluate the test, sensor, and algorithm effectiveness on predicting and/or discriminating older adult fallers from non-fallers. | Older adults (Aged > 60 years of age) | Average per study = 86 participants Total = 1896 participants | A diverse range of diagnostic performance was observed (Accuracy: 47.9–100%, Sensitivity: 16.7–100%, Specificity: 40–100%, AUC 0.65–0.89) for wearable device detection of falls. |
Results of the Relative Quality Assessment of the Included Systematic Reviews
| Study | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 | Q12 | Q13 | Q14 | Q15 | Q16 | Overall Quality of Study |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pang et al. 2019 [ | Y | Y | N | Y | N | Y | N | Y | PY | N | N/A | N/A | Y | Y | N/A | Y | |
| Nguyen et al. 2018 [ | Y | N | N | Y | N | Y | N | PY | N | N | N/A | N/A | N | N | N/A | Y | |
| Montesinos et al. 2018 [ | Y | N | Y | Y | N | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | |
| Chaudhuri et al. 2014 [ | Y | N | N | Y | Y | N | N | N | Y | N | N/A | N/A | N | N | N/A | N | |
| Silva de Lima et al. 2017 [ | Y | N | N | Y | N | N | N | N | N | N | N/A | N/A | N | N | N/A | Y | |
| Rucco et al. 2018 [ | Y | N | N | Y | N | N | N | Y | N | N | N/A | N/A | N | Y | N/A | Y | |
| Sun et al. 2018 [ | Y | N | Y | Y | N | N | N | PY | N | N | N/A | N/A | N | Y | N/A | Y |
This relative quality assessment tool follows the AMSTAR2 checklist [20]. This scale has four ratings for systematic reviews: critically low, low, moderate, high
Y Yes, PY Partial Yes, N No, NA Not applicable
Fig. 1PRISMA flowchart outlining the study selection process (Adapted from the PRISMA statement [18])
PRISMA Checklist
| Section/topic | # | Checklist item | Reported on page # |
|---|---|---|---|
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | 0 |
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 0 |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3–5 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 6–7 |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 5 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 9–10 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 5–6 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | 24–25 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 7 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 7–8 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 9–11 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 11 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | 9–11 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. | 9–11 |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 15 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 8–12 |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 8–11 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. | 8–12 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | 34–35 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | 8–12 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | N/A |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 11–12 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | N/A |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 13–17 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 15 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 16–17 |
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data), role of funders for the systematic review. | 18–19 |
PRISMA Checklist 2009: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097